Price T Rowe Associates Inc Alpine Immune Sciences, Inc. Transaction History

Price T Rowe Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $24.7 Million - $57.9 Million	1,392,942 Added 82.56%	3,080,220 $122 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $2.48 Million - $5.88 Million	290,834 Added 20.83%	1,687,278 $32.2 Million
Q3 2023 Nov 14, 2023	BUY	$10.13 - $13.98 $13.9 Million - $19.2 Million	1,374,704 Added 6323.39%	1,396,444 $16 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $14,466 - $25,189	2,115 Added 10.78%	21,740 $224,000
Q1 2023 May 15, 2023	BUY	$7.0 - $8.75 $1,568 - $1,960	224 Added 1.15%	19,625 $152,000
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $36,983 - $49,877	6,786 Added 53.79%	19,401 $143,000
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $86,917 - $118,454	12,615 New	12,615 $91,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.